Organon Expands Biosimilar Portfolio with PYZCHIVA® in Canada
Event summary
- Organon secures exclusive commercial rights to PYZCHIVA® (ustekinumab) in Canada, expanding its biosimilar portfolio to six products.
- PYZCHIVA® is a biosimilar referencing STELARA® (ustekinumab), used for treating plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.
- Samsung Bioepis retains development, manufacturing, and regulatory responsibilities while Organon handles commercialization.
- PYZCHIVA® is expected to launch in the Canadian market in 2026.
The big picture
This expansion reinforces Organon’s commitment to biosimilars, a growing segment in the pharmaceutical industry aimed at reducing healthcare costs. The deal aligns with broader trends of increasing biosimilar adoption to improve affordability and access to treatments for chronic conditions like psoriasis and inflammatory bowel disease. With six biosimilars now in its Canadian portfolio, Organon is positioning itself as a key player in the biosimilar market, potentially influencing pricing and market dynamics in the region.
What we're watching
- Market Penetration
- How PYZCHIVA® will compete with STELARA® in the Canadian market, given its biosimilar status.
- Regulatory Dynamics
- Whether the Canadian regulatory environment will support the swift approval and adoption of PYZCHIVA®.
- Execution Risk
- The pace at which Organon can integrate PYZCHIVA® into its existing biosimilar portfolio and commercialization strategy.
Related topics